GlaxoSmithKline plc is planning to use peptide technology from Angiochem Inc. to develop next-generation enzyme replacement therapies that target the CNS without lessening their effects in the periphery. They could replace current drugs that address only non-CNS symptoms of lysosomal storage disorders.

Under a deal at the end of February, Angiochem will apply its engineered peptide compound (EPiC) technology to an enzyme replacement therapy provided by GSK.